IMARC Group, a leading market research company, has recently releases report titled “Monkeypox Vaccine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032” The global monkeypox vaccine market size reached US$ 86.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 421.8 Million by 2032, exhibiting a growth rate (CAGR) of 18.85% during 2024-2032.
Request For Sample Copy of Report For More Detailed Market insight: https://www.imarcgroup.com/monkeypox-vaccine-market/requestsample
Factors Affecting the Growth of the Monkeypox Vaccine Industry:
- Global Health Initiatives and Funding Increases:
The rise in international focus on infectious diseases is driving the demand for vaccines against emerging threats like monkeypox. Governments, global health bodies, and private entities are increasingly investing in vaccine development and distribution frameworks to prevent widespread outbreaks. This rise in funding not only facilitates the accelerated development and approval of new vaccines but also enhances the manufacturing capabilities of pharmaceutical companies. As a result, the capacity to produce vaccines at scale and the ability to rapidly respond to emerging health crises are markedly improving.
- Rising Incidence of Monkeypox Cases:
The noticeable increase in monkeypox cases across multiple regions globally is supporting the growth of the market. This uptick is linked to several factors, including greater human interaction with animal vectors and international travel, which facilitates the cross-border transmission of the virus. The growing awareness among public health authorities and surveillance of monkeypox are leading to improved diagnosis rates, subsequently increasing the perceived need for vaccination. The urgent demand for effective preventive measures against a potential outbreak encourages healthcare systems and governments to procure and stockpile adequate vaccine supplies.
- Advancements in Vaccine Technology:
Recent technological advancements in vaccine research and development (R&D) are bolstering the market growth. Innovations, such as messenger ribonucleic acid (mRNA) vaccine technology, are being adapted for other infectious diseases, including monkeypox. These technologies allow for quicker development and potentially more effective vaccines, increasing their adoption rate. Moreover, the ability to adjust existing platforms to target new pathogens reduces the time and cost associated with vaccine development, making the process more efficient and scalable. This factor not only enhances the production capacity of vaccine manufacturers but also improves the global readiness to combat emerging infectious diseases.
Monkeypox Vaccine Market Report Segmentation:
By Type:
- Replication-competent
- Replication-deficient
Based on the type, the market has been bifurcated into replication-competent and replication-deficient.
By Route of Administration:
- Subcutaneous
- Percutaneous
Subcutaneous represents the largest segment as it is relatively easy to administer, requiring less skill than intramuscular injections.
By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Hospital pharmacy accounts for the majority of the market share owing to the wide range of medications available.
By End User:
- Hospitals
- Clinics
- Others
Hospitals hold the biggest market share due to the rising number of patients seeking effective healthcare to treat monkey pox.
Regional Insights:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America’s dominance in the monkeypox vaccine market is attributed to investment in drug research operations, leading to advanced technological developments in this field.
Global Monkeypox Vaccine Market Trends:
Increased public awareness about monkeypox and its transmission dynamics plays a significant role in driving vaccine demand. As awareness grows, so does the willingness of the public to receive vaccinations, influenced by targeted health communication strategies and public health campaigns. Furthermore, governments implementing robust health policies that include vaccination programs as part of their disease prevention and control plans also spur market growth. These policies often mandate vaccine procurement and administration, supported by public health advisories and educational campaigns that effectively increase community engagement and compliance. Thus, informed public behavior combined with proactive governmental strategies enhances the overall demand for monkeypox vaccines.
Other Key Points Covered in the Report:
- Porters Five Forces Analysis
- Value Chain Analysis
- Strategic Recommendations
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
